Evolving Role of CAR T-Cell Therapy in Mantle Cell Lymphoma
Brian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.
Emerging Treatment Strategies for Patients with MCL
Dr Brian Hill discusses the potential use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma (MCL) and reviews emerging treatment options for patients with MCL.
Unmet Needs and Future Directions in Mantle Cell Lymphoma
Brian Hill, MD, reviews unmet needs and future directions in the management of mantle cell lymphoma.
Role of CAR T-cell Therapy in Mantle Cell Lymphoma
Brian Hill, MD, reviews the role of CAR T-cell therapy in mantle cell lymphoma.
Mitigating CAR T–Related Toxicities in Mantle Cell Lymphoma
Brian Hill, MD, reviews strategies for mitigating toxicities associated with CAR T-cell therapy.
Results of the ZUMA-2 Trial in Relapsed/Refractory Mantle Cell Lymphoma
Brian Hill, MD, reviews practice-changing data from the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.
Second-Line Treatment Options in Mantle Cell Lymphoma
Brian Hill, MD, reviews second-line treatment options for patients with relapsed/refractory mantle cell lymphoma.
Frontline Treatment Options in Mantle Cell Lymphoma
Brian Hill, MD, reviews frontline treatment options for patients with mantle cell lymphoma.
73-Year-Old Man With Mantle Cell Lymphoma
Brian Hill, MD, reviews the case of a 73-year-old man with mantle cell lymphoma.
A 73-Year-Old Male With Mantle Cell Lymphoma
Brian Hill, MD, reviews the case of a 73-year-old man with mantle cell lymphoma and discusses the latest data and treatment approaches.
Safety Findings for Axi-Cel in Patients With DLBCL
Brian T. Hill, MD, PhD, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.
Real-World Data for Axi-Cel in Broader DLBCL Population
Brian T. Hill, MD, PhD, discusses data from a retrospective trial looking at the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with diffuse large B-cell lymphoma.
Investigating Combination Therapies in Mantle Cell Lymphoma
Brian T. Hill, MD, PhD, director of Lymphoid Malignancies at the Cleveland Clinic, discusses current combinations being investigated for the treatment of patients with mantle cell lymphoma.